Why Gastroenterology?
BioProphyl: Prof. Dr. Konturek, you are an experienced internist and gastroenterologist and serve as head physician at the Clinic for Internal Medicine II in Saalfeld. Can you briefly explain what motivated you to specialize in this field?
Prof. Dr. Konturek: Gastroenterology deals with the diagnosis, treatment, and prevention of diseases of the gastrointestinal tract and associated organs (pancreas, liver). It is a very exciting and dynamically developing field of internal medicine. On one hand, there are various diagnostic methods – especially endoscopy – for diagnosing and treating different gastrointestinal diseases.
On the other hand, there have been several important discoveries in gastroenterology in recent years. The most exciting to me is the role of the microbiome in health and its potential involvement in chronic diseases both within and outside the gut. These new insights may open up new possibilities for treating chronic intestinal diseases (irritable bowel syndrome, inflammatory bowel disease) and diseases outside the gut (metabolic disorders, autoimmune diseases, neurological and psychiatric conditions).
Explaining the Microbiome
BioProphyl: Your research focuses on the microbiome. Could you briefly explain what it is and how the microbiome can be influenced, both positively and negatively?
Prof. Dr. Konturek: The microbiome refers to the entirety of microbial organisms (bacteria, viruses, fungi, archaea). The largest microbiome is found in the gastrointestinal tract. However, other body regions (lungs, mouth, vagina, etc.) can also be colonized by the microbiome. The microbiome primarily represents a highly complex ecosystem that has a crucial influence on the development of the immune system.
Moreover, studies in recent years have shown that the microbiome communicates with other organs via various axes. These include, for example, the gut-brain axis, gut-lung axis, gut-liver axis, gut-skin axis, and gut-bone axis. The microbiome’s influence on distant organs is facilitated by the production of various metabolites by microbes. These include primarily short-chain fatty acids (butyrate, propionate, acetate), but also other substances like indoles and neurotransmitters (GABA, serotonin, dopamine, norepinephrine).
In a healthy gut (eubiosis), there is a balance between health-promoting and disease-promoting bacteria. A negative shift in this balanced ratio is referred to as dysbiosis. Increased colonization of the gut with inflammation-promoting bacteria can lead to various gastrointestinal symptoms such as bloating, abdominal pain, discomfort, nausea, vomiting, or chronic diarrhoea. Symptoms outside the gut, such as fatigue, can also come to the fore due to dysbiosis. For this reason, it is necessary to therapeutically influence the composition of the microbiome in cases of intestinal dysbiosis.
Currently, a number of microbiome-modulating therapies are available. These include prebiotics, probiotics, a combination of prebiotics and probiotics (synbiotics), faecal microbiota transplantation, and postbiotics. Prebiotics are usually poorly digestible carbohydrates (e.g., inulin) that support the growth and activity of beneficial bacteria. Probiotics are live microorganisms that are associated with positive health effects. Typical representatives of probiotics include lactobacilli and bifidobacteria.
Prebiotics and probiotics can be combined (synbiotics). These can support immunomodulation and colonization resistance against pathogenic germs. Faecal microbiota transplantation (FMT) involves transferring stool microbes from a healthy donor into the gut of a patient suffering from a dysbiosis-associated disease (e.g., recurrent Clostridium difficile infection, chronic inflammatory bowel disease, or irritable bowel syndrome). Based on experience, FMT can have much stronger microbiome-modulating effects than prebiotics or probiotics.
Finally, the microbiome can also be modulated with the help of postbiotics. These are preparations made from non-living organisms and/or their components, intended to provide health benefits to the host. Postbiotics include beneficial metabolic products, such as short-chain fatty acids (e.g., butyrate). Recently, a significant positive effect of butyrate on inflammation in patients with chronic inflammatory bowel disease was demonstrated for the first time.
Probiotics and Nutrition
BioProphyl: Many people want to positively influence their lifestyle through diet. Can you explain the role of probiotics in this context? And are there particular forms of probiotics that you, as a specialist, would recommend?
Prof. Dr. Konturek: Both our lifestyle and diet can have a profound effect on the composition of the gut microbiome. A lot of physical activity, avoiding smoking and alcohol consumption have a very positive effect on the intestinal microbiome. Diet plays a crucial role in the composition of the gut microbiome. Eubiosis can be supported by consuming fibre-rich foods, fruits, vegetables, and avoiding highly processed foods (ready-made products).
Criteria for Selecting Pre- and Probiotics
BioProphyl: What factors should be considered when selecting pre- and probiotics, and how important is the combination of prebiotics and probiotics (synbiotics)?
Prof. Dr. Konturek: It is known that probiotics differ in their properties. However, at present, personalized therapy with probiotics is not yet possible. Generally, I believe that therapy with a probiotic should last at least 3 months. If positive changes occur, the therapy can be extended accordingly. If the patient does not benefit, the therapy must be adjusted accordingly.
Probiotics of the Future
BioProphyl: Are there new developments or trends in probiotic research, such as next-generation probiotics? How do you see the future of pre- and probiotic research, and what challenges still need to be overcome?
Prof. Dr. Konturek: In recent years, there has been a trend towards the development of so-called next-generation probiotics. These are anaerobic bacteria that are difficult to culture. With the development of new sequencing and culturing methods, it is possible that these next-generation probiotics will be used therapeutically. Such probiotics include Roseburia intestinalis, Akkermansia muciniphila, Faecalibacterium prausnitzii, Bacteroides fragilis, Eubacterium hallii, Prevotella copri, and Parabacteroides goldsteinii. These probiotics have stronger therapeutic properties on the gut. They primarily support the restoration of the gut barrier. In addition, anti-carcinogenic, anti-inflammatory, and pronounced immunomodulatory effects are discussed. The biggest challenge is verifying the safety of these probiotics. We need a number of in vitro studies, especially clinical studies.
Regional Differences in Probiotics
BioProphyl: Are there cultural or regional differences in the use of pre- and probiotics that are particularly interesting?
Prof. Dr. Konturek: There are mainly cultural and regional differences in the consumption of probiotic foods. This is primarily due to different diets. While some countries focus on high-fat and highly processed diets (Western Europe, USA), the Mediterranean diet in southern European countries is very healthy and microbiome-supportive. Currently, the Mediterranean diet is considered the best in terms of maintaining healthy bacteria in the gut (eubiosis). In Asian countries, various probiotic foods are also widespread (kimchi, miso, natto, lassi, kecap, tempeh, etc.).
Tips for a Healthy Microbiome
BioProphyl: What recommendation would you like to make to maintain the microbiome in a normal state?
Prof. Dr. Konturek: In my opinion, the microbiome plays a central role in maintaining health. For this reason, I recommend that we take care of our microbiome on a daily basis: This includes consuming foods high in fibre, avoiding processed foods, and staying away from antibiotic therapies, as well as consuming fermented foods (sauerkraut, kefir, yoghurt, kimchi, miso, etc.). Only in this way, in my opinion, can we prevent the development of intestinal dysbiosis. The possibility of designing nutritional interventions specifically aimed at increasing certain bacterial metabolites to improve inflammatory health outcomes seems within reach.



